Wednesday, 5 April 2017

Cipla Gets US Regulatory nod for generic Epzicom Tablets

For more Live Stock future HNI Visit Us:-http://ripplesadvisory.com/stock-future-hni-.php or Get Free Trials Just Call @96-44-40-50-56.

Global pharmaceutical company Cipla on Tuesday announced that it has received final approval of the US Food and Drug Administration (USFDA) for the generic version of Epzicom tablets -- for the treatment of HIV-1 infection. 

"Abacavir and Lamivudine Tablets USP, 600 mg/300 mg, are AB-rated generic equivalents to the reference listed drug (RLD), Epzicom Tablets, 600 mg/300 mg of ViiV Healthcare Company and are indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection," the company said in a statement. 

"The product will cater to the US market and will be commercially available shortly," it added. According to IMS Health -- the American firm that provides information, services and technology for the healthcare industry -- Epzicom tablets had US sales of approximately $346.3 million for the 12-month period ending February.

No comments:

Post a Comment

Note: only a member of this blog may post a comment.